IN2015DN04209A - - Google Patents

Download PDF

Info

Publication number
IN2015DN04209A
IN2015DN04209A IN4209DEN2015A IN2015DN04209A IN 2015DN04209 A IN2015DN04209 A IN 2015DN04209A IN 4209DEN2015 A IN4209DEN2015 A IN 4209DEN2015A IN 2015DN04209 A IN2015DN04209 A IN 2015DN04209A
Authority
IN
India
Prior art keywords
methods
igf1r
cancers
insulin
constituent
Prior art date
Application number
Inventor
Peter Jeffery Leedman
Keith Michael Giles
Rikki Ann Mary Brown
Original Assignee
Univ Western Australia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2012904570A external-priority patent/AU2012904570A0/en
Application filed by Univ Western Australia filed Critical Univ Western Australia
Publication of IN2015DN04209A publication Critical patent/IN2015DN04209A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates generally to methods and compositions for the treatment of cancers expressing the type 1 insulin like growth factor receptor (IGF1R) or a constituent of an IGF1R signaling pathway in particular melanoma using the microRNA miR 7 5p. Also provided are methods for increasing the sensitivity of such cancers to therapeutic agents.
IN4209DEN2015 2012-10-18 2013-10-18 IN2015DN04209A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2012904570A AU2012904570A0 (en) 2012-10-18 Cancer therapy using miRNAs
PCT/AU2013/001208 WO2014059484A1 (en) 2012-10-18 2013-10-18 CANCER THERAPY USING miRNAs

Publications (1)

Publication Number Publication Date
IN2015DN04209A true IN2015DN04209A (en) 2015-10-16

Family

ID=50487345

Family Applications (1)

Application Number Title Priority Date Filing Date
IN4209DEN2015 IN2015DN04209A (en) 2012-10-18 2013-10-18

Country Status (5)

Country Link
US (1) US9795626B2 (en)
EP (1) EP2908830A4 (en)
CN (1) CN104994861B (en)
IN (1) IN2015DN04209A (en)
WO (1) WO2014059484A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2917348A1 (en) * 2012-11-06 2015-09-16 InteRNA Technologies B.V. Combination for use in treating diseases or conditions associated with melanoma, or treating diseases or conditions associated with activated b-raf pathway
ES2596711B1 (en) * 2015-07-09 2017-10-27 Fundacion Para La Investigacion Biomedica Del Hospital Universitario De La Paz Determination of the methylation and levels of a miRNA in response to a platinum-based antitumor compound
CN106367419A (en) * 2016-10-10 2017-02-01 徐州医科大学 Antisense oligonucleotide with neuroprotective effect, medicine composition and application thereof
AU2018209164B2 (en) 2017-01-17 2021-11-04 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
WO2018226802A1 (en) 2017-06-06 2018-12-13 The Johns Hopkins University Induction of synthetic lethality with epigenetic therapy
CN111183235A (en) * 2017-10-03 2020-05-19 基因序列有限公司 Methods for diagnosing, staging and monitoring melanoma using microRNA gene expression
CN109536497A (en) * 2018-11-28 2019-03-29 同济大学 The application of schistosoma japonicum infection and its component in human tumor prevention and treatment
US12058196B1 (en) 2020-03-26 2024-08-06 Amazon Technologies, Inc. Data transfer timeout management
US11750706B1 (en) * 2020-03-26 2023-09-05 Amazon Technologies, Inc. Data transmission time management

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2487258B1 (en) 2006-01-05 2014-10-01 The Ohio State University Research Foundation MicroRNA-based methods for the diagnosis of colon, pancreas and stomach cancer
EP2504014A4 (en) * 2009-11-24 2013-04-17 Univ Western Australia MODULATION OF EPIDERMAL GROWTH FACTOR RECEPTOR LIGANDS

Also Published As

Publication number Publication date
WO2014059484A1 (en) 2014-04-24
EP2908830A4 (en) 2016-11-30
CN104994861B (en) 2019-10-11
US20150366895A1 (en) 2015-12-24
US9795626B2 (en) 2017-10-24
EP2908830A1 (en) 2015-08-26
CN104994861A (en) 2015-10-21

Similar Documents

Publication Publication Date Title
IN2015DN04209A (en)
PH12015501738A1 (en) Androgen receptor modulators and uses thereof
TN2012000414A1 (en) Forms of rifaximin and uses thereof
PH12015500825B1 (en) Substituted benzene compounds
PH12014502095A1 (en) Estrogen receptor modulators and uses thereof
PH12013500481A1 (en) Estrogen receptor modulators and uses thereof
PH12012502419A1 (en) Estrogen receptor modulators and uses thereof
MX2013011922A (en) Substituted benzene compounds.
PH12014501351B1 (en) Fluorinated estrogen receptor modulators and uses thereof
GB201106750D0 (en) Novel compounds
IN2015DN02032A (en)
GB201106743D0 (en) Novel compounds
IN2014DN07414A (en)
NZ709059A (en) Immunotherapy with binding agents
MY185016A (en) Progenitor cells of mesodermal lineage
MX2015007180A (en) Modulators of the retinoid-related orphan receptor gamma (ror-gamma) for use in the treatment of autoimmune and inflammatory diseases.
EP2558124A4 (en) Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
MX2013004061A (en) Cyclosporin analogs.
IN2015MN00027A (en)
MX357284B (en) Quinone compounds for treating ape1 mediated diseases.
MX2014010537A (en) Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions.
MX2013004062A (en) Cyclosporin analogs.
MX2015005732A (en) Tricyclic compounds and methods of making and using same.
PH12012501548A1 (en) Compositions comprising sugar-cysteine products
MX2016002930A (en) Liver x receptor (lxr) modulators.